Tina Liedtky: Thermo Fisher Scientific Launches New Test to Help Guide Tacrolimus Dosing
Tina Liedtky, President of the Transplant Diagnostics Division at Thermo Fisher Scientific, shared a post on LinkedIn:
“In transplant medicine, every patient is unique. And healthcare teams need tools that enable them to provide personalized care.
To this end, I am excited to share that, today, Thermo Fisher Scientific launched a new laboratory developed test to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug that can help lower the risk of transplant rejection.
The right tacrolimus dose will vary from patient to patient.
With the new TacroType Pharmacogenetic Test, clinicians can better understand how their patient is likely to metabolize tacrolimus and respond to certain therapies.
This pharmacogenetic information is invaluable.
Learn more about what the new TacroType Pharmacogenetic Test means for patient care by reading the press release.”
Stay updated with Hemostasis Today.
-
Jul 17, 2026, 10:12Julien Perrin: Presenting Thalassemia Coagulation Research at ISTH 2026
-
Jul 17, 2026, 10:08Cihan Ay: Thank you for making ISTH 2026 such a remarkable congress
-
Jul 17, 2026, 10:06Laura Cunliffe: That Is a Wrap for Meg and Me at ISTH 2026 in Paris
-
Jul 17, 2026, 10:03Roberta Gualtierotti: Updating on the Standardization of ultrasound definitions in hemophilic arthropathy at the ISTH 2026
-
Jul 17, 2026, 09:57Hrushikesh Vyas – A Wonderful Week Presenting Inherited Thrombocytopenia Research at ISTH 2026
-
Jul 17, 2026, 09:42Samin Mohsenian: Proud to Receive a Top Poster Award at ISTH 2026
-
Jul 17, 2026, 09:36Wolfgang Miesbach: A Landmark Case of Supratherapeutic FIX Following Gene Therapy Presented at ISTH 2026
-
Jul 17, 2026, 09:28Lisa Astorga: Leaving ISTH 2026 Inspired by the Global Thrombosis and Hemostasis Community
-
Jul 17, 2026, 09:23Maxime Dely: Honored to Reach My 6th Plasma Donation of 2026